The global oncology clinical trial market size recorded US$ 13.64 billion in 2024, set to grow to US$ 14.36 billion in 2025 and projected to hit nearly US$ 22.85 billion by 2034, with a CAGR of 5.30% throughout the forecast timeline.
The adoption of inorganic growth strategies has help to improve the oncology clinical trial market
In August 2025, IndiaAl's Independent Business Division (BD), in a significant effort to incorporate state-of-the-art technology into oncology, in the Cancer Al & Technology Challenge (CATCH) Grant has been announced in collaboration with the National Cancer Grid (NCG) Program. The program will expedite the creation and application of Artificial Intelligence (AI) solutions to enhance cancer screening, diagnosis, treatment assistance, and operational effectiveness throughout the nation's healthcare system. The program will award selected project teams grants of up to 250 lakh so they can test AI innovations throughout the extensive hospital network of the NCG. Together, CG and IndiaAl will provide funding.
Target ID/validation → assay dev & screening → hit-to-lead/lead opt → translational biology & biomarkers → in-vitro/in-vivo efficacy → GLP tox → IND-enabling CMC & GMP.
Organizations: Sponsors/biotech (Roche/Genentech, Novartis, Merck, BMS, AstraZeneca, Pfizer, Amgen, Gilead/Kite); Preclinical CROs (Charles River, WuXi AppTec, Eurofins); Diagnostics/biomarkers (Foundation Medicine, Guardant Health, Roche Diagnostics, Agilent/Dako, NeoGenomics, Caris); Tools (Illumina, Thermo Fisher Scientific); CDMOs (Lonza, Catalent, WuXi Biologics, Samsung Biologics).
Protocol design & feasibility → site selection/start-up (IRB/EC) → patient recruitment → conduct & monitoring (incl. DCT) → data mgmt/biostats & safety → CMC supply → regulatory submissions/approval.
Organizations: CROs (IQVIA, PPD/Thermo Fisher, Parexel, ICON, Syneos, Labcorp Drug Dev); Sites/Networks (MD Anderson, Memorial Sloan Kettering, Dana-Farber, Mayo Clinic, Tata Memorial; NCI NCTN centers); IRBs/ECs (WCG IRB, Advarra); Tech platforms (Medidata, Veeva, Oracle Health Sciences); DCT/enrollment (Medable, Science 37, TrialJectory, Antidote, Deep 6 AI); Imaging & ePRO (Clario, Median Technologies, YPrime); Central labs (Q2 Solutions, Labcorp Central Labs); Regulators (FDA—OCE/CDER/CBER, EMA, MHRA, PMDA, CDSCO).
Awareness & matching → navigation & consent support → logistics/travel & stipends → adherence/PROs & home visits → survivorship & financial aid.
Organizations: NCI Cancer Information Service; Advocacy & navigation (American Cancer Society, CancerCare, Leukemia & Lymphoma Society, Susan G. Komen, Patient Advocate Foundation); Travel/financial aid (Lazarex Cancer Foundation, PAN Foundation); Home nursing/logistics (PCM Trials, Marken/UPS Healthcare); PRO/engagement (Clario, Evidation/Health); Real-world evidence & follow-up (Flatiron Health).
In April 2025, Professor Grant McArthur, Chief Executive Officer at VCCC Alliance stated that the Cancer Council Victoria and Cancer Research Fellowships Victoria (CFRV) initiative has launched a new four-year cancer research fellowship program that offers up to 40 postdoctoral researchers in their mid-career and 24 early-career cancer researchers. Prof. McArthur praised the decision, saying it was good news for cancer patients in Victoria because it made a critical investment in researchers in their early to mid-career stages.
Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com
